Abstract:Glycogen storage disease type VI (GSD-VI; also known as Hers disease, liver phosphorylase deficiency) is caused by mutations in the gene coding for glycogen phosphorylase (PYGL) leading to a defect in the degradation of glycogen. Since there are only about 40 patients described in literature, our knowledge about the course of the disease is limited. In order to evaluate the long-term outcome of patients with GSD-VI, an observational retrospective case study of six patients was performed at the University Children's Hospital Zurich. The introduction of small, frequent meals as well as cornstarch has led to normal growth in all patients and to normalization of liver transaminases in most patients. After starting the dietary regimen, there were no signs of hypoglycemia. However, three of six patients showed persistent elevation of triglycerides. Further, we identified four novel pathogenic PYGL mutations and describe here their highly variable impact on phosphorylase function.Conclusions: After establishing the diagnosis, dietary treatment led to metabolic stability and to prevention of hypoglycemia. Molecular genetics added important information for the understanding of the clinical variability in this disease. While outcome was overall excellent in all patients, half of the patients showed persistent hypertriglyceridemia even after initiating treatment.<table class="a-plus-plus table default-table float-no id-taba"><tbody class="a-plus-plus tbody"><tr class="a-plus-plus row"><td class="a-plus-plus entry nameend-c2 namest-c1">What is Known:• Glycogen storage disease type VI (GSD-VI) is a metabolic disorder causing a defect in glycogen degradation. Dietary treatment normally leads to metabolic stability and prevention of hypoglycemia.• However, our knowledge about the natural course of patients with GSD-VI is limited.</td></tr><tr class="a-plus-plus row"><td class="a-plus-plus entry nameend-c2 namest-c1">What is New:• While outcome was overall excellent in all patients, half of the patients showed persistent hypertriglyceridemia even after initiating treatment.• Molecular genetics added important information for the understanding of the clinical variability in this disease.</td></tr></tbody></table>

Expanding the p.(Arg85Trp) Variant-Specific Phenotype of HNF4A: Features of Glycogen Storage Disease, Liver Cirrhosis, Impaired Mitochondrial Function, and Glomerular Changes

Expanding the phenotype and metabolic basis of ATP6AP2-congenital disorder of glycosylation in a Chinese patient with a novel variant c.185G>A (p.Gly62Glu)

Glycogen storage disease type VI: clinical course and molecular background

Report of 7 cases of glycogen storage disease type VI and type IXa

Glycogen storage disease type IX: High variability in clinical phenotype

Clinical and Functional Characterization of Novel AGL Variants in Two Families with Glycogen Storage Disease Type III

The Phenotypic and Genetic Spectrum of Glycogen Storage Disease Type VI

Expanding the phenotypic spectrum of non-alcoholic fatty liver disease and hypertriglyceridemia

Clinical and biochemical heterogeneity between patients with glycogen storage disease type IA: the added value of CUSUM for metabolic control

Hepatic mitochondrial dysfunction is a feature of Glycogen Storage Disease Type Ia (GSDIa)

Natural history study of hepatic glycogen storage disease type IV and comparison to Gbe1ys/ys model

[Splicing abnormalities caused by a novel mutation in the PHKA2 gene in children with glycogen storage disease type IX]

A case study of a liver transplant-treated patient with glycogen storage disease type Ia presenting with multiple inflammatory hepatic adenomas: an analysis of clinicopathologic and genetic data

Glycogen storage disease Ia complicated with multiple hepatic adenomas: a case report and literature review

A patient with glycogen storage disease type Ia combined with chronic hepatitis B infection: a case report

Clinical features and PHKG2 gene mutation analysis of 5 Chinese patients with glycogen storage disease Ⅸc

Misdiagnosis as steatohepatitis in a family with mild glycogen storage disease type 1a.

Case report: Comprehensive exploration of a novel PFKM mutation in glycogen storage disease Type VII

Disease-associated programming of cell memory in glycogen storage disorder type 1a

Liver Glycogen Phosphorylase Deficiency Leads to Profibrogenic Phenotype in a Murine Model of Glycogen Storage Disease Type VI

Metabolic Profiling in Human Fibroblasts Enables Subtype Clustering in Glycogen Storage Disease